Overview
Reunion Neuroscience is developing RE104, a novel psychedelic compound with a shorter duration of action than psilocybin, targeting postpartum depression and major depressive disorder. Their approach aims to improve practicality of psychedelic-assisted therapy.
More in Mental Health Tech
Latest industry news
It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
2026-06-23 · Product
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 · Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 · Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 · Industry
Company details
Category
💙 Mental Health Tech
Location
Montreal, Canada
Funding
Public · NASDAQ: REUN
Website
reunionneuroscience.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →